136 related articles for article (PubMed ID: 37996193)
1. Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial.
Ceriello A; Prattichizzo F; Berra CC; Caballero AE
Lancet Diabetes Endocrinol; 2023 Dec; 11(12):894-895. PubMed ID: 37996193
[No Abstract] [Full Text] [Related]
2. Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial.
Vural Keskinler M; Telci Caklili O; Oguz A
Lancet Diabetes Endocrinol; 2023 Dec; 11(12):894. PubMed ID: 37996194
[No Abstract] [Full Text] [Related]
3. Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial.
Ahmed A; Anker SD; Butler J; Bakris GL; Bhatt DL; Fonarow GC; Packer M
Lancet Diabetes Endocrinol; 2023 Dec; 11(12):892-894. PubMed ID: 37996192
[No Abstract] [Full Text] [Related]
4. Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial - Authors' reply.
Xie Y; Al-Aly Z
Lancet Diabetes Endocrinol; 2023 Dec; 11(12):895-896. PubMed ID: 37996195
[No Abstract] [Full Text] [Related]
5. Intensive glucose lowering arm of diabetes trial is stopped after excess deaths.
Mayor S
BMJ; 2008 Feb; 336(7641):407. PubMed ID: 18292149
[No Abstract] [Full Text] [Related]
6. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
[TBL] [Abstract][Full Text] [Related]
7. Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance.
Inagaki N; Nangaku M; Sakata Y; Sasaki K; Mori-Anai K; Iwasaki T; Hamada K
Adv Ther; 2022 Jan; 39(1):674-691. PubMed ID: 34853985
[TBL] [Abstract][Full Text] [Related]
8. Use of Real-World Data to Emulate a Clinical Trial and Support Regulatory Decision Making: Assessing the Impact of Temporality, Comparator Choice, and Method of Adjustment.
Abrahami D; Pradhan R; Yin H; Honig P; Baumfeld Andre E; Azoulay L
Clin Pharmacol Ther; 2021 Feb; 109(2):452-461. PubMed ID: 32767673
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
[TBL] [Abstract][Full Text] [Related]
10. Effects of glucose-lowering on outcome incidence in diabetes mellitus and the modulating role of blood pressure and other clinical variables: overview, meta-analysis of randomized trials.
Thomopoulos C; Bazoukis G; Ilias I; Tsioufis C; Makris T
J Hypertens; 2019 Oct; 37(10):1939-1949. PubMed ID: 31157748
[TBL] [Abstract][Full Text] [Related]
11. Development and Validation of the Real-World Progression in Diabetes (RAPIDS) Model.
Basu A; Sohn MW; Bartle B; Chan KCG; Cooper JM; Huang E
Med Decis Making; 2019 Feb; 39(2):137-151. PubMed ID: 30654704
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes.
Kabadi UM
Ann Intern Med; 2021 Jan; 174(1):140. PubMed ID: 33460546
[No Abstract] [Full Text] [Related]
13. Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes.
Tsapas A; Karagiannis T; Avgerinos I; Matthews DR; Bekiari E
Ann Intern Med; 2021 Jan; 174(1):141. PubMed ID: 33460545
[No Abstract] [Full Text] [Related]
14. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of exenatide in Korean patients with type 2 diabetes inadequately controlled with oral hypoglycemic agents: an observational study in a real clinical practice.
Hwang YC; Kim A; Jo E; Yang Y; Cho JH; Lee BW
BMC Endocr Disord; 2017 Oct; 17(1):68. PubMed ID: 29065865
[TBL] [Abstract][Full Text] [Related]
16. Intensified glucose lowering in type 2 diabetes: time for a reappraisal.
Yudkin JS; Richter B; Gale EA
Diabetologia; 2010 Oct; 53(10):2079-85. PubMed ID: 20686748
[No Abstract] [Full Text] [Related]
17. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
Tandon N; Ali MK; Narayan KM
Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
[TBL] [Abstract][Full Text] [Related]
18. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
19. Trial Compares Glucose-Lowering Drugs for Type 2 Diabetes.
Slomski A
JAMA; 2022 Oct; 328(16):1581. PubMed ID: 36282260
[No Abstract] [Full Text] [Related]
20. Liraglutide for the treatment of type 2 diabetes.
Shyangdan D; Cummins E; Royle P; Waugh N
Health Technol Assess; 2011 May; 15 Suppl 1():77-86. PubMed ID: 21609656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
